-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzamend Neuro Phase 1/2A AL001 lithium fMRI data wins poster slot at SfN Neuroscience 2026

PUBT·08/20/2026 12:00:52
Listen to the news
Alzamend Neuro Phase 1/2A AL001 lithium fMRI data wins poster slot at SfN Neuroscience 2026
  • Alzamend Neuro secured a Neuroscience 2026 poster slot for Phase 1/2A neuroimaging results on AL001, an organic lithium salt.
  • Findings have not been presented yet; the poster is scheduled for Nov. 18, 2026 in Washington.
  • Data indicate AL001 treatment was associated with measurable shifts in brain network activity over time.
  • Management framed the dataset as supporting evidence of brain engagement, adding to prior blood and tissue lithium observations from the trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.